Waters Corporation has entered into an agreement to acquire Wyatt Technology for US$1.36 billion in cash, subject to certain adjustments.
BioAgilytix Labs describes 360biolabs as the most comprehensive contract research organisation in Australia.
FLIR Systems will now be included in Teledyne Technologies' Digital Imaging segment and operate under the name Teledyne FLIR.
Trajan Scientific and Medical has completed its acquisition of the MyHealthTest blood testing service for an undisclosed sum.
MBF Bioscience is expanding its two-photon and laser scanning technology capabilities by acquiring Vidrio Technologies.
Thermo Fisher Scientific has entered into a definitive agreement to acquire Mesa Biotech and completed its acquisition of Henogen.
Regional Health Care Group (RHCG) will distribute Osprey Medical's DyeVert contrast minimisation devices across Australia and New Zealand for the first time.
Illumina has entered into a definitive agreement to acquire GRAIL — a healthcare company whose mission is focused on multi-cancer early detection.
Inflazome, based on a research partnership between The University of Queensland and Trinity College Dublin, has been acquired for an upfront cash payment of €380m.
Illumina has a new addition to its portfolio: genomic compression-software company Enancio, based in Cesson-Sévigné, France.
Metrohm Australia has announced that, as of 1 March 2020, it is the exclusive distributor for ELGA LabWater in Australia for the PURELAB and CENTRA ranges.
Abcam has announced the asset purchase of the gene editing platform and oncology product portfolio of Applied StemCell for life science research and diagnostic markets.
Abcam has announced the successful completion of the acquisition of Expedeon's Proteomics and Immunology business, which includes Innova and TGR Biosciences, as of 1 January 2020.
The Alvéole platform allows users to convert an existing microscope into an automated bioengineering system for the engineering of smart cell culture substrates.
Abcam has announced its acquisition of the entire live cell line and lysates portfolio of EdiGene, a Chinese company focused on developing genome editing technologies into novel therapeutics.